Liver Steatosis and Fibrosis in Non-Celiac Wheat Sensitivity Patients: a Prospective Study
A legfontosabb adatok
- Ki végzi
- University of Palermo
- Hol
- Olaszország2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 250 fő, tervezett
- Kezdés
- 2024. jan. 1.
- Várható befejezés
- 2030. dec. 31.
- A vizsgálat típusa
- Megfigyeléses, 3 csoport
- A vizsgált kezelések
- Prevalence and severity of liver steatosis and fibrosis,
- A regiszteradat frissítve
- 2026. augusztus 11.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults newly diagnosed with non-celiac wheat sensitivity, irritable bowel syndrome/functional dyspepsia, or celiac disease. It checks how often they have fatty liver and liver scarring.
- Életkor
- Over 18 and under 65 years
- Nem
- All sexes
- A betegség stádiuma
- Wheat sensitivity group: symptoms caused by wheat, confirmed by a blinded wheat test after an elimination diet of at least 4 weeks. IBS/FD group: diagnosed by Rome IV criteria, with no food-related symptoms and no response to a gluten-free diet. Celiac group: confirmed celiac disease that improved on a gluten-free diet.
- Korábbi kezelés
- An abdominal ultrasound must have been done before diagnosis, before any diet or treatment change. No steroids or anti-inflammatory drugs (NSAIDs) in the 2 weeks before the duodenal biopsy.
- Biomarker vagy leletérték
- Wheat sensitivity group: negative celiac antibody tests (DPG, tTG, EMA) and negative wheat allergy tests. No villous atrophy in people carrying HLA DQ2 and/or DQ8. Celiac group: positive anti-tTG IgA and/or IgG and villous atrophy on duodenal biopsy.
A részvétel fő kizáró okai
- Pregnancy or breastfeeding
- Chronic alcohol intake (>30 g/day for men, >20 g/day for women) or drug abuse
- Chronic hepatitis B or C, autoimmune or inherited metabolic liver disease
- Inflammatory bowel disease, other digestive diseases, neurological, major psychiatric or immune disorders
- Long-term use of drugs linked to fatty liver, such as glucocorticoids, estrogens, tamoxifen, amiodarone, methotrexate
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- age >18 and <65 years
- subjects with wheat-dependent symptoms, both gastrointestinal and extra-intestinal
- negativity of IgA and IgG anti-deamidated gliadin peptide (DPG) antibodies, immunoglobulin (Ig)A and IgG anti-tissue transglutaminase (tTG) antibodies, and anti-endomysial antibodies (EMA)
- absence of duodenal villous atrophy, documented in all patients carrying the human leukocyte antigen (HLA) DQ2 and/or DQ8 haplotypes (therefore regardless of the negativity of celiac disease (CeD)-specific serum antibodies), evaluated when the patients had consumed a minimum of 100g of pasta and/or bread a day, for at least 45 days
- absence of IgE-mediated wheat allergy (WA): negative skin prick-test and/or specific serum IgE assay for wheat, gluten and gliadin)
- resolution of symptoms on a strict standard elimination diet (i.e. extended oligoantigenic, excluding wheat, cow's milk, egg, tomato and chocolate and other foods self-reported by the patient as causing symptoms), followed for at least 4 weeks, and the recurrence of the same symptoms after double-blind placebo-controlled challenge (DBPCC) with wheat (for further details see below)
- complete medical records
- duration of follow-up longer than 12 months after initial diagnosis, with at least 2 outpatient visits during the follow-up period
- age >18 and <65 years
- subjects diagnosed with IBS/FD and other functional gastrointestinal disorders, according to the Rome IV classification, 1 who did not specifically report symptoms/signs, whether gastrointestinal or extra-intestinal, following ingestion of wheat or other foods and who did not respond to gluten-free diet (GFD)
- age >18 and <65 years
- subjects with gastrointestinal and extra-intestinal wheat-dependent symptoms that meet the diagnostic criteria of CeD 2: positivity of anti-tTG IgA and/or IgG antibodies and evidence of villous atrophy, according to the Marsh-Oberhuber classification, demonstrated by histology on duodenal biopsy
- clinical response to the GFD: resolution of gastrointestinal and/or extra-intestinal symptoms
Ki nem vehet részt
- drug abuse
- treatment with steroids and/or non-steroidal anti-inflammatory drugs in the 2 weeks before duodenal biopsy
- absence of abdominal ultrasound (US) imaging performed before diagnosis (i.e. before starting the wheat-free/gluten-free diet in NCWS and CeD patients, and before any lifestyle modifications and/or drug/prebiotic/probiotic intake in IBS/FD patients)
- chronic long-term treatment with drugs associated with both macrovesicular (glucocorticoids, estrogens, tamoxifen, amiodarone, methotrexate, and 5-fluorouracil) and microvesicular (glucocorticoids, valproic acid, tetracycline, and zidovudine) steatosis
- diagnosis of chronic inflammatory bowel disease or other organic pathologies affecting the digestive system (e.g., wheat allergy, microscopic colitis, diverticulitis, segmental colitis associated with diverticulosis, etc.), neurological diseases, major psychiatric disorders, infectious diseases, immunological deficiencies, and impairments limiting physical activity
- lack of clinical follow-up for at least 12 months after diagnosis with >2 outpatient visits during the follow-up period; Additional exclusion criteria related to liver steatosis and other liver diseases
- chronic hepatotropic virus infections [hepatitis B virus (HBV) and hepatitis C virus (HCV)]
- autoimmune liver diseases
- congenital metabolic liver diseases (e.g. alpha-1 antitrypsin deficiency, hemochromatosis, Wilson's disease, porphyria, other storage diseases, etc.)
- self-exclusion of wheat from the diet and refusal to reintroduce it for diagnostic purposes, before entering the study
- pregnancy or breastfeeding
- incomplete medical records
- incomplete clinical records, lacking the data considered for the present study
- chronic alcohol intake (>30 g/day for men and >20 g/day for women)
Egyéb feltételek
- The inclusion/exclusion criteria used to select the study population have been previously validated in other retrospective studies. Additional exclusion criteria related to steatosis and other liver diseases and specifically required for this study were adopted
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Hypothesizing an intestinal barrier impairment as a common pathophysiological substrate of both Non Celiac Wheat Sensitivity (NCWS) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MAFLD), in a retrospective cohort study (data not yet published), demographic, clinical, laboratory and histology data of NCWS patients at the time of diagnosis, were analyzed and compared to control subjects with Irritable Bowel Syndrome/Functional Dyspepsia (IBS/FD) and freshly diagnosed Celiac Disease (CeD). NCWS diagnosis was performed by a double-blind placebo-controlled wheat challenge. Steatosis was confirmed by ultrasound examination. Our retrospective data showed that the frequency of liver of steatosis was lower in NCWS than in IBS patients. In addition, it seems that pre-diagnosis avoidance of wheat in NCWS correlates with protection from steatosis. A subset of NCWS patients, recently exposed to wheat, with clinical features suggesting increased IP, seems to be predisposed to liver steatosis and fibrosis.
A teljes eredeti leírásKevesebb
To validate the results of the retrospective study, the researchers planned the present prospective study, to analyze the prevalence of liver steatosis and fibrosis, evaluated by ultrasound (US) examination, FibroScan analysis [CAP (Controlled Attenuation Parameter) and LSM (Liver Stiffness Measurement) values], FIB-4 (Fibrosis-4) index, and NFS [Non-alcoholic fatty liver disease (NAFLD) Fibrosis Score], in patients with NCWS at the time of diagnosis, comparing them with two control populations of newly diagnosed IBS/FD and CeD patients.
A vizsgálat 3 csoportja
- Non-Celiac Wheat Sensitivity (NCWS) patients
Non-Celiac Wheat Sensitivity (NCWS) patients, consecutively diagnosed by double-blind placebo-controlled challenge (DBPCC) with wheat
Kezelés: Prevalence and severity of liver steatosis and fibrosis,
- Irritable Bowel Syndrome/Functional Dyspepsia (IBS/FD) patients unrelated to food allergies
Control population of Irritable Bowel Syndrome/Functional Dyspepsia (IBS/FD) patients unrelated to food (including wheat) allergies/intolerances
Kezelés: Prevalence and severity of liver steatosis and fibrosis,
- Celiac Disease (CeD) patients
Control populations of Celiac Disease (CeD) patients
Kezelés: Prevalence and severity of liver steatosis and fibrosis,
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Prevalence and Risk Factors of Liver Steatosis and Fibrosis in Non-Celiac Wheat Sensitivity Patients: a Prospective Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07750535: ki vehet részt
- A regiszteradat frissítve
- 2026. augusztus 11.